reSee.it - Related Video Feed

The episode features Jillian Michaels and Brigham Buhler discussing a healthcare system they view as corrupted by powerful entities in pharma and insurance. Buhler recounts his arc from a drug rep to founder of Ways to Well and Revive, detailing how Big Pharma and Big Insurance operate as a cartel that denies, delays, and obstructs patient care to protect profits. He argues that patients are frequently steered away from comprehensive, preventive health strategies toward expensive, disease-driven interventions, highlighting the tension between access to care and the realities of a business-first system. The conversation centers on how misaligned incentives drive up costs while undermining outcomes, from bloated drug prices to opaque rebate structures managed by pharmacy benefit managers (PBMs). They delve into compounding pharmacies as a double-edged sword: essential for affordable, personalized medications and often caricatured by critics, yet targeted by litigation from big manufacturers. Buhler explains the rigorous safety standards some compounding shops uphold, including sterile compounding and third-party validations, while noting the broader problem of 510(k) loopholes and insufficient human trials for many medical devices. The pair also scrutinize GLP-1s and the broader trend of overprescribing, arguing that root causes—nutrition, diet, lifestyle—are underexploited levers for health but underfunded by a system geared toward pharmacologic fixes and chronic revenue. They discuss the cost barriers to advanced diagnostics and preventive testing, pharmacogenetic testing, and the role of comprehensive panels in shaping personalized care. Buhler envisions a future where AI-driven monitoring, predictive testing, and cash-pay clinics like Ways to Well empower individuals to take sovereignty over their health, reduce dependence on insurers, and extend healthspan rather than merely chasing disease management. The dialogue also touches RFK, Casey Means, Callie, and a broader movement advocating diet, prevention, and autonomy, urging listeners to invest in proactive health strategies and to scrutinize the incentives shaping modern medicine. The episode closes with a practical note on affordability, stressing that deeper health insights need not be prohibitively expensive and that a comprehensive baseline can be attained for a few hundred dollars yearly. topics Big Pharma, Big Insurance, healthcare cartels, denials and delays, compounding pharmacies, 510k loopholes, FDA oversight, GLP-1s, preventive medicine, nutrition and lifestyle, predictive medicine, AI in healthcare, Ways to Well, Wastewell, pharmacogenetics, healthspan, RFK, Casey Means, Callie otherTopics Bayer and historical drug testing, opioid crisis, Sackler family history, insulin pricing and PBMs, shadow bans in media, the role of regulation in innovation, privacy concerns with AI health monitoring booksMentioned Bottle of Lies

Pharma’s business model, Peter C. Gøtzsche argues, is organized crime. The pattern shows drug companies repeatedly committing crimes, bribing politicians and top officials, and paying off doctors to influence research and marketing. He notes that some of the largest drug firms have been fined billions, yet profits from sales exceed those penalties, allowing corrupt practices to continue. He says corruption spans research, marketing, and regulation, citing bribery of FDA commissioners and health ministers and broad influence over physicians. He contrasts the United States with Europe, noting U.S. healthcare consumes about 18% of GDP and relies on middlemen and aggressive drug use, while Nordic public systems offer universal care. He contends prescription drugs are a leading cause of death, including opioids, Motrin, and psychiatric medications, and that reducing their use by up to 90% could yield a healthier population. Beyond drugs, the interview turns to psychiatry and diagnosis. The guest criticizes the DSM for expanding medical labeling of ordinary experiences into disorders, calling ADHD a non-existent natural category and joking about a parade of diagnoses that would cover the middle. He recounts a dinner where four people tested positive for ADHD on a casual test, showing how easily psychiatric labels proliferate. He recalls warnings from veteran psychiatrists about overreliance on drugs for mental health and advocates psychotherapy as an alternative. Later, the discussion shifts to antidepressants, where studies show minimal placebo benefit and frequent sexual side effects, with some reports suggesting increased suicidality. The conversation then dives into vaccines and public health, with the guest expressing skepticism about licensing and mandates. He discusses the measles vaccine as life-saving in some cases but argues that screening and vaccination programs can yield mixed results, including cases where vaccination protocols might not extend life expectancy and can drive overtreatment. He addresses the HPV vaccine controversy, presenting data from internal reports and his book on Merck and drug regulator practices. He also critiques mammography screening, arguing that it does not reduce total mortality and can lead to unnecessary procedures. He has written about deadly psychiatry and organized denial, and emphasizes open scientific debate.